Nantahala Capital Management, LLC
Position in AKBA — Akebia Therapeutics, Inc.
CIK 1472322
New Canaan, CT
Position in AKBA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,780,000
-$440,000 QoQ
Shares Held
2,000,000
0.0% QoQ
Ownership
0.722%
of shares outstanding
% of Portfolio
0.18%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
14 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AKBA Over Time
Shares Held
Position Value (USD)
Derivatives in AKBA
reported options exposure · as of Mar 31, 2022CallValue
$693,444
CallShares
965,800
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Nantahala Capital Management, LLC holds $146,306,398 across 10 Drug Manufacturers - Specialty & Generic names. AKBA ranks #8 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AMRX |
Amneal Pharmaceuticals, Inc.
|
2,844,108 | $35,352,262 | |
| 2 | ETON |
Eton Pharmaceuticals, Inc.
|
1,175,951 | $29,022,470 | |
| 3 | EOLS |
Evolus, Inc.
|
6,376,857 | $26,208,882 | |
| 4 | ADCT |
ADC Therapeutics SA
|
5,597,433 | $20,990,373 | |
| 5 | BCRX |
Biocryst Pharmaceuticals Inc
|
1,987,397 | $18,920,019 | |
| 6 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
535,684 | $7,446,007 | |
| 7 | AYTU |
Aytu Biopharma, Inc
|
1,086,812 | $2,966,996 | |
| 8 | AKBA |
Akebia Therapeutics, Inc.
This page
|
2,000,000 | $2,780,000 |
All Filings in AKBA
Export CSV
15 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,780,000 | 2,000,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,220,000 | 2,000,000 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $5,460,000 | 2,000,000 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $7,280,000 | 2,000,000 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $3,840,000 | 2,000,000 | Shares | Sole | 2025-05-15 | |
| 2022-03-31 | $693,444 | 965,800 | Call | Sole | 2022-05-13 | |
| 2021-12-31 | $2,260,000 | 1,000,000 | Call | Sole | 2022-02-14 | |
| 2021-12-31 | $11,115,956 | 4,918,565 | Shares | Sole | 2022-02-14 | |
| 2021-09-30 | $14,337,201 | 4,978,195 | Shares | Sole | 2021-11-15 | |
| 2021-06-30 | $19,594,538 | 5,170,063 | Shares | Sole | 2021-08-16 | |
| 2021-03-31 | $17,435,522 | 5,150,819 | Shares | Sole | 2021-05-14 | |
| 2020-12-31 | $19,713,363 | 7,040,487 | Shares | Sole | 2021-02-16 | |
| 2020-09-30 | $14,424,023 | 5,746,623 | Shares | Sole | 2020-11-16 | |
| 2020-06-30 | $82,853,087 | 6,101,111 | Shares | Sole | 2020-08-14 | |
| 2020-03-31 | $49,720,843 | 6,559,478 | Shares | Sole | 2020-05-14 | |
| No filing history on record for this holder in this stock. | ||||||